A Phase 3 interventional study of Infanrix hexa and Pediarix in Poliomyelitis, Diphtheria and Haemophilus Influenzae Type b, sponsored by GlaxoSmithKline. Completed at 43 sites in United States. Open to participants aged 6 Weeks to 12 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-11-27.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Poliomyelitis — none open to participants now, none under way, none of them phase 3. diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine · Poliomyelitis.
Among the 14 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Poliomyelitis, this one is the 5th largest by enrollment, is the only one that started in 2014, is one of 7 in phase 3, and was the 12th registered.
275 studies on the registry are indexed under Poliomyelitis; 19 are open to participants now.
Browse Poliomyelitis studies →None of the 14 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Poliomyelitis is open now. The open studies under Poliomyelitis, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 11 Poliomyelitis studies recruiting now, none (0%) set no upper age limit and 11 (100%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.
This study: 6 Weeks to 12 Weeks · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 1 started in 2014.
This study's enrollment of 585 is above the median of 478 across 250 interventional studies indexed under Poliomyelitis.
Median enrollment 467 across the 14 interventional studies. Of the 14 that completed or were terminated, 10 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 14 have an industry lead sponsor. The 2 most frequent:
GlaxoSmithKline is the lead sponsor of 3,652 studies on the registry; 118 are open to participants now.
Of its 267 completed or terminated interventional studies of FDA-regulated products, 241 (90%) have results posted.
44 studies in Poliomyelitis by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 43 finished, 30 (70%) have results posted.
Among the 44 studies in Poliomyelitis by GlaxoSmithKline, this one is the 11th largest by enrollment of the 41 interventional ones that give a count, is the only one that started in 2014, is one of 20 in phase 3, and was the 41st registered.
GlaxoSmithKline’s Poliomyelitis studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Poliomyelitis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 44 in Poliomyelitis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the immunogenicity and safety of GSK Biologicals' Infanrix hexa vaccine when administered to healthy infants as primary vaccination at 2, 4 and 6 months of age, co-administered with Prevnar and Rotarix with a booster dose of GSK Biologicals' Infanrix and Hiberix vaccines at 15-18 months of age.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Planned administration/administration of a vaccine not foreseen by the study protocol within the period starting from 30 days before the first vaccination until 30 days after Dose 3 (Epoch 001, primary vaccination) and from 30 days before the booster Dose 4 until 30 days after booster Dose 4 (Epoch 002, booster vaccination), i.e. the end of the study:
Acute disease and/or fever at the time of enrolment.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects between, and including, 6 and 12 weeks of age at the time of the vaccination received, in the Primary Phase of the study, 3 doses of Infanrix hexa (lot A, lot B or lot C as per the group allocation) co-administered with Prevnar13 at 2, 4 and 6 months of age and Rotarix at 2 and 4 months of age. The injectable vaccines were administered by intramuscular injection in the anterolateral thigh, while Rotarix was administered orally. Subjects received a booster dose of Infanrix and Hiberix at 15-18 months of age by intramuscular injection in the anterolateral thigh.
Biological: Infanrix hexa · Biological: Infanrix · Biological: Hiberix · Biological: Prevnar13 · Biological: Rotarix
Subjects between, and including, 6 and 12 weeks of age at the time of the vaccination received, in the Primary Phase of the study, 3 doses of Pediarix and ActHIB co-administered with Prevnar13 at 2, 4 and 6 months of age and Rotarix at 2 and 4 months of age. The injectable vaccines were administered by intramuscular injection in the anterolateral thigh, while Rotarix was administered orally. Subjects received a booster dose of Infanrix and ActHIB at 15-18 months of age by intramuscular injection in the anterolateral thigh.
Biological: Pediarix · Biological: ActHIB · Biological: Infanrix · Biological: Prevnar13 · Biological: Rotarix
Subjects between, and including, 6 and 12 weeks of age at the time of the vaccination received, in the Primary Phase of the study, 3 doses of Pentacel and Engerix co-administered with Prevnar13 at 2, 4 and 6 months of age and Rotarix at 2 and 4 months of age. The injectable vaccines were administered by intramuscular injection in the anterolateral thigh, while Rotarix was administered orally. Subjects received a booster dose of Pentacel at 15-18 months of age by intramuscular injection in the anterolateral thigh.
Biological: Pentacel · Biological: Engerix-B · Biological: Prevnar13 · Biological: Rotarix
3 doses administered intramuscularly in the right thigh.
3 doses administered intramuscularly in the right thigh
4 doses administered intramuscularly in the upper left thigh
4 doses administered intramuscularly in the right thigh
2 or 3 doses administered intramuscularly in the upper left thigh
1 dose administered intramuscularly in the right thigh
1 dose administered intramuscularly in the left thigh
3 doses administered intramuscularly in the lower left thigh
2 doses administered orally
Antibody Concentrations for Pertussis Toxoid (Anti-PT), Filamentous Hemagglutinin (Anti-FHA) and Pertactin (Anti-PRN).
Concentrations were expressed as geometric mean concentrations (GMCs) for the following cut-offs:2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA, and 2.187 IU/mL for anti-PRN. The results for the Infanrix hexa Group and Pediarix Group were the primary outcome variables.
Time frame: At Month 5, one month after the third dose of the primary vaccination.
Number of Seropositive Subjects for Anti-PT, Anti-FHA and Anti-PRN.
A seropositive subject was defined as a subject with antibody concentrations above to or equal to (≥) 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA, and 2.187 IU/mL for anti-PRN.
Time frame: At Month 5, one month after the third dose of the primary vaccination.
Number of Seroprotected Subjects Against Tetanus (T).
A seroprotected subject was defined a a subject with antibody concentrations ≥ 0.1 IU/mL.
Time frame: At Month 5, one month after the third dose of the primary vaccination.
Number of Seroprotected Subjects Against Diphtheria (D).
A seroprotected subject was defined a a subject with antibody concentrations ≥ 0.1 IU/mL.
Time frame: At Month 5, one month after the third dose of the primary vaccination.
Antibody Concentrations for Anti-T.
Concentrations were expressed as GMCs for the seroprotection cut-off of 0.1 IU/mL.
Time frame: At Month 5, one month after the third dose of the primary vaccination
Antibody Concentrations for Anti-D.
Concentrations were expressed as GMCs for the seroprotection cut-off of 0.1 IU/mL.
Time frame: At Month 5, one month after the third dose of the primary vaccination
Number of Seroprotected Subjects Against Anti-polio Types 1, 2 and 3.
A seroprotected subject was defined as a subject with anti-polio types 1, 2 and 3 titres ≥ 8 dilution.
Time frame: At Month 5, one month after the third dose of the primary vaccination
Antibody Titres for Anti-polio Types 1, 2 and 3.
Titres were expressed as geometric mean titres (GMTs) for the cut-off of 8 dilution.
Time frame: At Month 5, one month after the third dose of the primary vaccination
Number of Seroprotected Subjects Against Polyribosyl Ribitol Phosphate (Anti-PRP).
A seroprotected subject was defined as a subject with anti-PRP concentrations ≥ 0.15 µg/mL.
Time frame: At Month 5, one month after the third dose of the primary vaccination
Number of Subjects With Anti-PRP Antibody Concentrations ≥ 1 µg/mL.
The cut-off for this assay was an anti-PRP concentration ≥ 1 µg/mL.
Time frame: At Month 5, one month after the third dose of the primary vaccination
Antibody Concentrations for Anti-PRP.
Antibody concentrations were expressed as GMCs for the assay cut-off of 1 µg/mL.
Time frame: At Month 5, one month after the third dose of the primary vaccination
Number of Seroprotected Subjects Against Hepatitis B (Anti-HBs).
A seroprotected subject was defined as a subject with anti-HBs antibody concentrations ≥ 10 mili-International units per mililiter (mIU/mL).
Time frame: At Month 5, one month after the third dose of the primary vaccination
Antibody Concentrations for Anti-HBs.
Antibody concentrations were expressed as GMCs for the seroprotection cut-off of 10 mIU/mL.
Time frame: At Month 5, one month after the third dose of the primary vaccination
Number of Subjects With Solicited Local Symptoms.
The solicited local symptoms assessed were pain, redness and swelling. Any = any reports of the specific symptom irrespective of intensity grade; above or equal (≥); Grade 2 Redness/Swelling: \> 5 millimeters (mm); Grade 3 Redness/Swelling: \> 20 mm; Grade 2 Pain = Moderate: cries/protests on touch; Grade 3 Pain = Severe: Cries when limb is moved/spontaneously painful. Grade = G; Medical Advice = MA.
Time frame: During the 4-day (Days 0-3) post-vaccination period following Dose 1
Number of Subjects With Solicited Local Symptoms.
The solicited local symptoms assessed were pain, redness (Red) and swelling (Swe). Any = any reports of the specific symptom irrespective of intensity grade; above or equal (≥); Grade 2 Redness/Swelling: \> 5 millimeters (mm); Grade 3 Redness/Swelling: \> 20 mm; Grade 2 Pain = Moderate: cries/protests on touch; Grade 3 Pain = Severe: Cries when limb is moved/spontaneously painful. Grade = G; Medical Advice = MA.
Time frame: During the 4-day (Days 0-3) post-vaccination period following Dose 2
Number of Subjects With Solicited Local Symptoms.
The solicited local symptoms assessed were pain, redness and swelling. Any = any reports of the specific symptom irrespective of intensity grade; above or equal (≥); Grade 2 Redness/Swelling: \> 5 millimeters (mm); Grade 3 Redness (Red)/Swelling (Swe): \> 20 mm; Grade 2 Pain = Moderate: cries/protests on touch; Grade 3 Pain = Severe: Cries when limb is moved/spontaneously painful. Grade = G; Medical Advice = MA
Time frame: During the 4-day (Days 0-3) post-vaccination period following Dose 3
Number of Subjects With Solicited Local Symptoms.
The solicited local symptoms assessed were pain, redness and swelling. Any = any reports of the specific symptom irrespective of intensity grade; above or equal (≥); Grade 2 Redness (Red)/Swelling (Swe): \> 5 millimeters (mm); Grade 3 Redness/Swelling: \> 20 mm; Grade 2 Pain = Moderate: cries/protests on touch; Grade 3 Pain = Severe: Cries when limb is moved/spontaneously painful. Grade = G; Medical Advice = MA.
Time frame: During the 4-day (Days 0-3) post-vaccination period following any dose.
Number of Subjects With Solicited General Symptoms.
The solicited general symptoms assessed were Drowsiness, Irritability/Fussiness, Loss Of Appetite and Fever (defined as temperature ≥ 38.0°C). Any = any reports of the specific symptom irrespective of intensity grade; Grade 2 (G2) Drowsiness = Drowsiness that interfered with normal activity; Grade 2 Irritability/Fussiness = Moderate: Cried more than usual/interfered with normal activity; Grade 2 Loss of appetite = Ate less than usual/interfered with normal activity; Grade 2 Fever: \> 39.0 °C; Grade 3 (G3) Drowsiness/Irritability/Fussiness = symptom that prevented normal activity; Grade 3 Loss of appetite = Did not eat at all; Grade 3 Fever: \> 40.0 °C; Related (Rel) = Symptom which was assessed by the investigator as related to vaccination.
Time frame: During the 4-day (Days 0-3) post-vaccination period following Dose 1.
Number of Subjects With Solicited General Symptoms.
The solicited general symptoms assessed were Drowsiness, Irritability/Fussiness, Loss Of Appetite and Fever (defined as temperature ≥ 38.0°C). Any = any reports of the specific symptom irrespective of intensity grade; Grade 2 (G2) Drowsiness = Drowsiness that interfered with normal activity; Grade 2 Irritability/Fussiness = Moderate: Cried more than usual/interfered with normal activity; Grade 2 Loss of appetite = Ate less than usual/interfered with normal activity; Grade 2 Fever: \> 39.0 °C; Grade 3 (G3) Drowsiness/Irritability/Fussiness = symptom that prevented normal activity; Grade 3 Loss of appetite = Did not eat at all; Grade 3 Fever: \> 40.0 °C; Related (Rel) = Symptom which was assessed by the investigator as related to vaccination.
Time frame: During the 4-day (Days 0-3) post-vaccination period following Dose 2.
Number of Subjects With Solicited General Symptoms.
The solicited general symptoms assessed were Drowsiness, Irritability/Fussiness, Loss Of Appetite and Fever (defined as temperature ≥ 38.0°C). Any = any reports of the specific symptom irrespective of intensity grade; Grade 2 (G2) Drowsiness = Drowsiness that interfered with normal activity; Grade 2 Irritability/Fussiness = Moderate: Cried more than usual/interfered with normal activity; Grade 2 Loss of appetite = Ate less than usual/interfered with normal activity; Grade 2 Feve:r \> 39.0 °C; Grade 3 (G3) Drowsiness/Irritability/Fussiness = symptom that prevented normal activity; Grade 3 Loss of appetite = Did not eat at all; Grade 3 Fever: \> 40.0 °C; Related (Rel) = Symptom which was assessed by the investigator as related to vaccination.
Time frame: During the 4-day (Days 0-3) post-vaccination period following Dose 3.
Number of Subjects With Solicited General Symptoms.
The solicited general symptoms assessed were Drowsiness, Irritability/Fussiness, Loss Of Appetite and Fever (defined as temperature ≥ 38.0°C). Any = any reports of the specific symptom irrespective of intensity grade; Grade 2 (G2) Drowsiness = Drowsiness that interfered with normal activity; Grade 2 Irritability/Fussiness = Moderate: Cried more than usual/interfered with normal activity; Grade 2 Loss of appetite = Ate less than usual/interfered with normal activity; Grade 2 Fever: \> 39.0 °C; Grade 3 (G3) Drowsiness/Irritability/Fussiness = symptom that prevented normal activity; Grade 3 Loss of appetite = Did not eat at all; Grade 3 Fever: \> 40.0 °C; Related (Rel) = Symptom which was assessed by the investigator as related to vaccination.
Time frame: During the 4-day (Days 0-3) post-vaccination period following any dose.
Number of Subjects With Specific Adverse Events (AEs).
Occurrence of specific adverse events, i.e., new onset chronic diseases (e.g. autoimmune disorders, asthma, type I diabetes and allergies)
Time frame: From Month 0 up to 6 months post primary-vaccination (Month 10)
Number of Subjects With Unsolicited AEs.
An unsolicited AE is any AE (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
Time frame: During the 31-day (Days 0-30) post-primary vaccination period.
Number of Subjects With Serious Adverse Events (SAEs).
SAEs were defined as medical occurrences that resulted in death, were life threatening, required hospitalization or prolongation of hospitalization or resulted in disability/incapacity.
Time frame: From Month 0 up to 6 months post-primary vaccination (Month 10)
Number of Seroprotected Subjects Against Anti-T.
A seroprotected subject was defined a subject with antibody concentrations ≥ 0.1 IU/mL.
Time frame: At Visit 5 [At Month 13-16 before the booster dose (Dose 4)] and at Visit 6 (At Month 14-17 one month after the booster dose (Dose 4)]
Number of Seroprotected Subjects Against Anti-D.
A seroprotected subject was defined a subject with antibody concentrations ≥ 0.1 IU/mL.
Time frame: At Visit 5 [At Month 13-16 before the booster dose (Dose 4)] and at Visit 6 (At Month 14-17 one month after the booster dose (Dose 4)]
Antibody Concentrations for Anti-T.
Concentrations were expressed as GMCs for the seropositivity cut-off of 0.1 IU/mL.
Time frame: At Visit 5 [At Month 13-16 before the booster dose (Dose 4)] and at Visit 6 [At Month 14-17 one month after the booster dose (Dose 4)]
Antibody Concentrations for Anti-D.
Concentrations were expressed as GMCs for the seropositivity cut-off of 0.1 IU/mL.
Time frame: At Visit 5 [At Month 13-16 before the booster dose (Dose 4)] and at Visit 6 [At Month 14-17 one month after the booster dose (Dose 4)]
Number of Seropositive Subjects for Anti-PT, Anti-FHA and Anti-PRN.
A seropositive subject was defined as a subject with antibody concentrations above to or equal to (≥) 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA, and 2.187 IU/mL for anti-PRN.
Time frame: At Visit 5 [Month 13-16 before the booster dose (Dose 4)] and at Visit 6 [Month 14-17 one month after the booster dose (Dose 4)]
Antibody Concentrations for Anti-PT, Anti-FHA and Anti-PRN.
Concentrations were expressed as geometric mean concentrations (GMCs) for the following cut-offs:2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA, and 2.187 IU/mL for anti-PRN.
Time frame: At Visit 5 [Month 13-16 before the booster dose (Dose 4)] and at Visit 6 [Month 14-17 one month after the booster dose (Dose 4)]
Number of Subjects With a Booster Response for Anti-PT, Anti-FHA and Anti-PRN.
Booster response to PT, FHA and PRN antigens was defined as: * For subjects with pre-vaccination antibody concentration below the assay cut off, post-vaccination antibody concentration equal or above 4 times the assay cut-off. * For subjects with pre-vaccination antibody concentration between the assay cut off and below 4 times the assay cut-off, post-vaccination antibody concentration equal or above 4 times the pre-vaccination antibody concentration. * For subjects with pre-vaccination antibody concentration equal or above 4 times the assay cut-off, post-vaccination antibody concentration of at least two times the pre-vaccination antibody concentration. The assay cut off is 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA, and 2.187 IU/mL for anti-PRN.
Time frame: At Visit 6 [At Month 14-17 one month after the booster dose (Dose 4)]
Number of Seroprotected Subjects Against Anti-PRP.
A seroprotected subject was defined as a subject with anti-PRP concentrations ≥ 0.15 µg/mL.
Time frame: At Visit 5 [At Month 13-16 before the booster dose (Dose 4)] and at Visit 6 [At Month 14-17 one month after the booster dose (Dose4)]
Number of Subjects With Anti-PRP Antibody Concentrations ≥ 1 µg/mL.
The cut-off for this assay was an anti-PRP concentration ≥ 1 µg/mL.
Time frame: At Visit 5 [At Month 13-16 before the booster dose (Dose 4)] and at Visit 6 [At Month 14-17 one month after the booster dose (Dose4)]
Antibody Concentrations for Anti-PRP.
Antibody concentrations were expressed as GMCs for the seroprotection cut-off of 1 µg/mL.
Time frame: At Visit 5 [At Month 13-16 before the booster dose (Dose 4)] and at Visit 6 [At Month 14-17 one month after the booster dose (Dose 4)]
Number of Seroprotected Subjects Against Anti-polio Types 1, 2 and 3.
A seroprotected subject was defined as a subject with anti-polio types 1, 2 and 3 titres ≥ 8 dilution.
Time frame: At Visit 5 [At Month 13-16 before the booster dose (Dose 4)]
Antibody Titres for Anti-polio Types 1, 2 and 3.
Titres were expressed as geometric mean titres (GMTs) for the cut-off of 8 dilution.
Time frame: At Visit 5 [At Month 13-16 before the booster dose (Dose 4)]
Number of Seroprotected Subjects Against Anti-HBs.
A seroprotected subject was defined as a subject with anti-HBs antibody concentrations ≥ 10 mIU/mL.
Time frame: At Visit 5 [At Month 13-16 before the booster dose (Dose 4)]
Antibody Concentrations for Anti-HBs.
Antibody concentrations were expressed as GMCs for the seroprotection cut-off of 10 mIU/mL.
Time frame: At Visit 5 [At Month 13-16 before the booster dose (Dose 4)]
Number of Subjects With Solicited Local Symptoms.
The solicited local symptoms assessed were pain, redness and swelling. Any = any reports of the specific symptom irrespective of intensity grade; above or equal (≥); Grade 2 Redness (Red)/Swelling (Swe): \> 5 millimeters (mm); Grade 3 Redness/Swelling: \> 20 mm; Grade 2 Pain = Moderate: cries/protests on touch; Grade 3 Pain = Severe: Cries when limb is moved/spontaneously painful. Grade = G; Medical Advice = MA.
Time frame: During the 4-day (Days 0-3) post-booster vaccination.
Number of Subjects With Solicited General Symptoms.
The solicited general symptoms assessed were Drowsiness, Irritability/Fussiness, Loss Of Appetite and Fever (defined as temperature ≥ 38.0°C). Any = any reports of the specific symptom irrespective of intensity grade; Grade 2 (G2) Drowsiness = Drowsiness that interfered with normal activity; Grade 2 Irritability/Fussiness = Moderate: Cried more than usual/interfered with normal activity; Grade 2 Loss of appetite = Ate less than usual/interfered with normal activity; Grade 2 Fever: \> 39.0 °C and ≤ 40.0 °C; Grade 3 (G3) Drowsiness/Irritability/Fussiness = symptom that prevented normal activity; Grade 3 Loss of appetite = Did not eat at all; Grade 3 Fever: \> 40.0 °C; Related (Rel) = Symptom which was assessed by the investigator as related to vaccination.
Time frame: During the 4-day (Days 0-3) post-booster vaccination.
Number of Subjects With Specific AEs.
Occurrence of specific adverse events, i.e., new onset chronic diseases (e.g. autoimmune disorders, asthma, type I diabetes and allergies)
Time frame: During the 31-day (Days 0-30) post-booster vaccination.
Number of Subjects With Unsolicited AEs.
An unsolicited AE is any AE (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
Time frame: During the 31-day (Days 0-30) post-booster vaccination.
Number of Subjects With SAEs.
SAEs were defined as medical occurrences that resulted in death, were life threatening, required hospitalization or prolongation of hospitalization or resulted in disability/incapacity.
Time frame: During the 31-day (Days 0-30) post-booster vaccination.
This study was conducted in 43 centers in the United States of America (USA).
| Milestone | Infanrix Hexa Group | Pediarix Group | Pentacel Group |
|---|---|---|---|
| Started | 195 | 194 | 196 |
| Completed | 161 | 158 | 157 |
| Not completed | 34 | 36 | 39 |
| Withdrew: Adverse event | 1 | 0 | 1 |
| Withdrew: Lost to follow-up | 14 | 18 | 15 |
| Withdrew: Other | 7 | 9 | 6 |
| Withdrew: Sponsor study termination | 0 | 0 | 1 |
| Withdrew: Protocol violation | 7 | 2 | 8 |
| Withdrew: Withdrawal by subject | 5 | 7 | 8 |
Concentrations were expressed as geometric mean concentrations (GMCs) for the following cut-offs:2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA, and 2.187 IU/mL for anti-PRN. The results for the Infanrix hexa Group and Pediarix Group were the primary outcome variables.
| IU/mL | Infanrix Hexa Group | Pediarix Group | Pentacel Group |
|---|---|---|---|
| Anti-PT | 43.2 (38.1 to 48.9) | 48.3 (42.7 to 54.5) | 24.2 (21.1 to 27.7) |
| Anti-FHA | 106.3 (95.0 to 119.0) | 122.7 (109.9 to 137.0) | 59.9 (51.7 to 69.3) |
| Anti-PRN | 57.4 (49.5 to 66.6) | 46.9 (39.9 to 55.3) | 33.0 (27.8 to 39.1) |
A seropositive subject was defined as a subject with antibody concentrations above to or equal to (≥) 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA, and 2.187 IU/mL for anti-PRN.
| Participants | Infanrix Hexa Group | Pediarix Group | Pentacel Group |
|---|---|---|---|
| Anti-PT | 146 | 148 | 148 |
| Anti-FHA | 146 | 149 | 149 |
| Anti-PRN | 146 | 148 | 148 |
A seroprotected subject was defined a a subject with antibody concentrations ≥ 0.1 IU/mL.
| Participants | Infanrix Hexa Group | Pediarix Group | Pentacel Group |
|---|---|---|---|
| Number of Seroprotected Subjects Against Tetanus (T). | 146 | 149 | 148 |
A seroprotected subject was defined a a subject with antibody concentrations ≥ 0.1 IU/mL.
| Participants | Infanrix Hexa Group | Pediarix Group | Pentacel Group |
|---|---|---|---|
| Number of Seroprotected Subjects Against Diphtheria (D). | 142 | 144 | 149 |
Concentrations were expressed as GMCs for the seroprotection cut-off of 0.1 IU/mL.
| IU/mL | Infanrix Hexa Group | Pediarix Group | Pentacel Group |
|---|---|---|---|
| Antibody Concentrations for Anti-T. | 2.458 (2.195 to 2.753) | 2.633 (2.338 to 2.966) | 2.012 (1.768 to 2.290) |
Concentrations were expressed as GMCs for the seroprotection cut-off of 0.1 IU/mL.
| IU/mL | Infanrix Hexa Group | Pediarix Group | Pentacel Group |
|---|---|---|---|
| Antibody Concentrations for Anti-D. | 1.777 (1.551 to 2.036) | 1.648 (1.44 to 1.886) | 1.249 (1.095 to 1.425) |
A seroprotected subject was defined as a subject with anti-polio types 1, 2 and 3 titres ≥ 8 dilution.
| Participants | Infanrix Hexa Group | Pediarix Group | Pentacel Group |
|---|---|---|---|
| Anti-polio 1 | 137 | 134 | 135 |
| Anti-polio 2 | 133 | 131 | 134 |
| Anti-polio 3 | 129 | 132 | 124 |
Titres were expressed as geometric mean titres (GMTs) for the cut-off of 8 dilution.
| titres | Infanrix Hexa Group | Pediarix Group | Pentacel Group |
|---|---|---|---|
| Anti-polio 1 | 546.9 (447.7 to 668.0) | 604.1 (495.9 to 736.0) | 319.5 (256.8 to 397.5) |
| Anti-polio 2 | 483.5 (394.2 to 593.0) | 567.7 (448.8 to 718.1) | 283.0 (229.4 to 349.2) |
| Anti-polio 3 | 722.2 (577.4 to 903.4) | 927.0 (740.7 to 1160.3) | 294.6 (221.6 to 391.7) |
A seroprotected subject was defined as a subject with anti-PRP concentrations ≥ 0.15 µg/mL.
| Participants | Infanrix Hexa Group | Pediarix Group | Pentacel Group |
|---|---|---|---|
| Number of Seroprotected Subjects Against Polyribosyl Ribitol Phosphate (Anti-PRP). | 146 | 151 | 154 |
The cut-off for this assay was an anti-PRP concentration ≥ 1 µg/mL.
| Participants | Infanrix Hexa Group | Pediarix Group | Pentacel Group |
|---|---|---|---|
| Number of Subjects With Anti-PRP Antibody Concentrations ≥ 1 µg/mL. | 85 | 145 | 130 |
Antibody concentrations were expressed as GMCs for the assay cut-off of 1 µg/mL.
| µg/mL | Infanrix Hexa Group | Pediarix Group | Pentacel Group |
|---|---|---|---|
| Antibody Concentrations for Anti-PRP. | 1.348 (1.076 to 1.688) | 9.258 (7.362 to 11.642) | 5.717 (4.363 to 7.492) |
A seroprotected subject was defined as a subject with anti-HBs antibody concentrations ≥ 10 mili-International units per mililiter (mIU/mL).
| Participants | Infanrix Hexa Group | Pediarix Group | Pentacel Group |
|---|---|---|---|
| Number of Seroprotected Subjects Against Hepatitis B (Anti-HBs). | 134 | 138 | 133 |
Antibody concentrations were expressed as GMCs for the seroprotection cut-off of 10 mIU/mL.
| mIU/mL | Infanrix Hexa Group | Pediarix Group | Pentacel Group |
|---|---|---|---|
| Antibody Concentrations for Anti-HBs. | 2258.8 (1910.7 to 2670.4) | 1886.0 (1565.6 to 2271.9) | 1053.4 (780.2 to 1422.4) |
The solicited local symptoms assessed were pain, redness and swelling. Any = any reports of the specific symptom irrespective of intensity grade; above or equal (≥); Grade 2 Redness/Swelling: \> 5 millimeters (mm); Grade 3 Redness/Swelling: \> 20 mm; Grade 2 Pain = Moderate: cries/protests on touch; Grade 3 Pain = Severe: Cries when limb is moved/spontaneously painful. Grade = G; Medical Advice = MA.
| Participants | Infanrix Hexa Group | Pediarix Group | Pentacel Group |
|---|---|---|---|
| Any Pain, ActHIB/Engerix | NA | 123 | 100 |
| ≥ G 2 Pain, ActHIB/Engerix | NA | 66 | 45 |
| G 3 Pain, ActHIB/Engerix | NA | 22 | 10 |
| MA Pain, ActHIB/Engerix | NA | 1 | 0 |
| Any Pain, Infanrix hexa/Pediarix/Pentacel | 94 | 113 | 115 |
| ≥ G 2 Pain, Infanrix hexa/Pediarix/Pentacel | 40 | 65 | 51 |
| G 3 Pain, Infanrix hexa/Pediarix/Pentacel | 8 | 17 | 12 |
| MA Pain, Infanrix hexa/Pediarix/Pentacel | 1 | 0 | 0 |
| Any Redness, ActHIB/Engerix | NA | 63 | 55 |
| ≥ G 2 Redness, ActHIB/Engerix | NA | 19 | 12 |
| G 3 Redness, ActHIB/Engerix | NA | 8 | 1 |
| MA Redness, ActHIB/Engerix | NA | 1 | 0 |
| Any Redness, Infanrix hexa/Pediarix/Pentacel | 47 | 56 | 57 |
| ≥ G 2 Redness, Infanrix hexa/Pediarix/Pentacel | 15 | 15 | 20 |
| G 3 Redness, Infanrix hexa/Pediarix/Pentacel | 3 | 4 | 3 |
| MA Redness, Infanrix hexa/Pediarix/Pentacel | 0 | 0 | 0 |
| Any Swelling, ActHIB/Engerix | NA | 41 | 39 |
| ≥ G 2 Swelling, ActHIB/Engerix | NA | 14 | 14 |
| G 3 Swelling, ActHIB/Engerix | NA | 6 | 3 |
| MA Swelling, ActHIB/Engerix | NA | 1 | 0 |
| Any Swelling, Infanrix hexa/Pediarix/Pentacel | 31 | 35 | 45 |
| ≥ G 2 Swelling, Infanrix hexa/Pediarix/Pentacel | 10 | 14 | 24 |
| G 3 Swelling, Infanrix hexa/Pediarix/Pentacel | 2 | 3 | 11 |
| MA Swelling, Infanrix hexa/Pediarix/Pentacel | 0 | 0 | 0 |
The solicited local symptoms assessed were pain, redness (Red) and swelling (Swe). Any = any reports of the specific symptom irrespective of intensity grade; above or equal (≥); Grade 2 Redness/Swelling: \> 5 millimeters (mm); Grade 3 Redness/Swelling: \> 20 mm; Grade 2 Pain = Moderate: cries/protests on touch; Grade 3 Pain = Severe: Cries when limb is moved/spontaneously painful. Grade = G; Medical Advice = MA.
| Participants | Infanrix Hexa Group | Pediarix Group | Pentacel Group |
|---|---|---|---|
| Any Pain, ActHIB/Engerix | NA | 104 | 6 |
| ≥ G 2 Pain, ActHIB/Engerix | NA | 47 | 2 |
| G 3 Pain, ActHIB/Engerix | NA | 9 | 0 |
| MA Pain, ActHIB/Engerix | NA | 0 | 0 |
| Any Pain,Infanrix/Pediarix/Pentacel | 84 | 108 | 93 |
| ≥G2 Pain,Infanrix/Pediarix/Pentacel | 25 | 44 | 31 |
| G3 Pain,Infanrix/Pediarix/Pentacel | 1 | 7 | 6 |
| MA Pain, Infanrix/Pediarix/Pentacel | 0 | 0 | 0 |
| Any Redness, ActHIB/Engerix | NA | 66 | 5 |
| ≥ G 2 Redness, ActHIB/Engerix | NA | 17 | 1 |
| G 3 Redness, ActHIB/Engerix | NA | 1 | 0 |
| MA Redness, ActHIB/Engerix | NA | 0 | 0 |
| Any Red, Infanrix/Pediarix/Pentacel | 59 | 61 | 64 |
| ≥G2 Red,Infanrix/Pediarix/Pentacel | 15 | 12 | 15 |
| G 3 Red, Infanrix/Pediarix/Pentacel | 3 | 3 | 2 |
| MA Red, Infanrix/Pediarix/Pentacel | 0 | 0 | 0 |
| Any Swelling, ActHIB/Engerix | NA | 40 | 3 |
| ≥ G 2 Swelling, ActHIB/Engerix | NA | 11 | 0 |
| G 3 Swelling, ActHIB/Engerix | NA | 1 | 0 |
| MA Swelling, ActHIB/Engerix | NA | 0 | 0 |
| Any Swe, Infanrix/Pediarix/Pentacel | 41 | 40 | 42 |
| ≥G2 Swe, Infanrix/Pediarix/Pentacel | 10 | 12 | 7 |
| G 3 Swe, Infanrix/Pediarix/Pentacel | 2 | 2 | 3 |
| MA Swe, Infanrix/Pediarix/Pentacel | 0 | 0 | 0 |
The solicited local symptoms assessed were pain, redness and swelling. Any = any reports of the specific symptom irrespective of intensity grade; above or equal (≥); Grade 2 Redness/Swelling: \> 5 millimeters (mm); Grade 3 Redness (Red)/Swelling (Swe): \> 20 mm; Grade 2 Pain = Moderate: cries/protests on touch; Grade 3 Pain = Severe: Cries when limb is moved/spontaneously painful. Grade = G; Medical Advice = MA
| Participants | Infanrix Hexa Group | Pediarix Group | Pentacel Group |
|---|---|---|---|
| Any Pain, ActHIB/Engerix | NA | 93 | 75 |
| ≥ G 2 Pain, ActHIB/Engerix | NA | 41 | 25 |
| G 3 Pain, ActHIB/Engerix | NA | 7 | 5 |
| MA Pain, ActHIB/Engerix | NA | 1 | 0 |
| Any Pain, Infanrix/Pediarix/Pentacel | 67 | 90 | 76 |
| ≥ G2 Pain, Infanrix/Pediarix/Pentacel | 18 | 39 | 20 |
| G3 Pain, Infanrix/Pediarix/Pentacel | 0 | 7 | 7 |
| MA Pain, Infanrix/Pediarix/Pentacel | 0 | 1 | 0 |
| Any Red, ActHIB/Engerix | NA | 69 | 51 |
| ≥ G 2 Red, ActHIB/Engerix | NA | 7 | 9 |
| G 3 Red, ActHIB/Engerix | NA | 1 | 2 |
| MA Red, ActHIB/Engerix | NA | 0 | 0 |
| Any Red, Infanrix/Pediarix/Pentacel | 63 | 66 | 56 |
| ≥G2 Red, Infanrix/Pediarix/Pentacel | 7 | 12 | 11 |
| G3 Red, Infanrix/Pediarix/Pentacel | 1 | 3 | 0 |
| MA Red, Infanrix/Pediarix/Pentacel | 0 | 1 | 0 |
| Any Swe, ActHIB/Engerix | NA | 42 | 37 |
| ≥ G 2 Swe, ActHIB/Engerix | NA | 7 | 7 |
| G 3 Swe, ActHIB/Engerix | NA | 1 | 0 |
| MA Swe, ActHIB/Engerix | NA | 0 | 0 |
| Any Swe, Infanrix/Pediarix/Pentacel | 43 | 44 | 35 |
| ≥ G2 Swe, Infanrix/Pediarix/Pentacel | 7 | 10 | 4 |
| G3 Swe, Infanrix/Pediarix/Pentacel | 1 | 3 | 0 |
| MA Swe, Infanrix/Pediarix/Pentacel | 0 | 1 | 0 |
The solicited local symptoms assessed were pain, redness and swelling. Any = any reports of the specific symptom irrespective of intensity grade; above or equal (≥); Grade 2 Redness (Red)/Swelling (Swe): \> 5 millimeters (mm); Grade 3 Redness/Swelling: \> 20 mm; Grade 2 Pain = Moderate: cries/protests on touch; Grade 3 Pain = Severe: Cries when limb is moved/spontaneously painful. Grade = G; Medical Advice = MA.
| Participants | Infanrix Hexa Group | Pediarix Group | Pentacel Group |
|---|---|---|---|
| Any Pain, ActHIB/Engerix | NA | 148 | 127 |
| ≥ G 2 Pain, ActHIB/Engerix | NA | 96 | 62 |
| G 3 Pain, ActHIB/Engerix | NA | 30 | 14 |
| MA Pain, ActHIB/Engerix | NA | 2 | 0 |
| Any Pain, Infanrix/Pediarix/Pentacel | 127 | 151 | 147 |
| ≥ G2 Pain, Infanrix/Pediarix/Pentacel | 58 | 93 | 80 |
| G3 Pain, Infanrix/Pediarix/Pentacel | 8 | 27 | 22 |
| MA Pain, Infanrix/Pediarix/Pentacel | 1 | 1 | 0 |
| Any Red, ActHIB/Engerix | NA | 108 | 77 |
| ≥ G 2 Red, ActHIB/Engerix | NA | 38 | 20 |
| G 3 Red, ActHIB/Engerix | NA | 10 | 3 |
| MA Red, ActHIB/Engerix | NA | 1 | 0 |
| Any Red, Infanrix/Pediarix/Pentacel | 94 | 98 | 87 |
| ≥ G2 Red, Infanrix/Pediarix/Pentacel | 27 | 32 | 37 |
| G3 Red, Infanrix/Pediarix/Pentacel | 7 | 9 | 5 |
| MA Red, Infanrix/Pediarix/Pentacel | 0 | 1 | 0 |
| Any Swe, ActHIB/Engerix | NA | 78 | 64 |
| ≥ G 2 Swe, ActHIB/Engerix | NA | 25 | 18 |
| G 3 Swe, ActHIB/Engerix | NA | 7 | 3 |
| MA Swe, ActHIB/Engerix | NA | 1 | 0 |
| Any Swe, Infanrix/Pediarix/Pentacel | 73 | 70 | 72 |
| ≥ G2 Swe, Infanrix/Pediarix/Pentacel | 20 | 26 | 26 |
| G3 Swe, Infanrix/Pediarix/Pentacel | 4 | 7 | 12 |
| MA Swe, Infanrix/Pediarix/Pentacel | 0 | 1 | 0 |
The solicited general symptoms assessed were Drowsiness, Irritability/Fussiness, Loss Of Appetite and Fever (defined as temperature ≥ 38.0°C). Any = any reports of the specific symptom irrespective of intensity grade; Grade 2 (G2) Drowsiness = Drowsiness that interfered with normal activity; Grade 2 Irritability/Fussiness = Moderate: Cried more than usual/interfered with normal activity; Grade 2 Loss of appetite = Ate less than usual/interfered with normal activity; Grade 2 Fever: \> 39.0 °C; Grade 3 (G3) Drowsiness/Irritability/Fussiness = symptom that prevented normal activity; Grade 3 Loss of appetite = Did not eat at all; Grade 3 Fever: \> 40.0 °C; Related (Rel) = Symptom which was assessed by the investigator as related to vaccination.
| Participants | Infanrix Hexa Group | Pediarix Group | Pentacel Group |
|---|---|---|---|
| Any Drowsiness | 114 | 143 | 149 |
| ≥ G 2 Drowsiness | 36 | 56 | 53 |
| G 3 Drowsiness | 3 | 8 | 12 |
| Rel Drowsiness | 112 | 136 | 141 |
| G3 Rel Drowsiness | 3 | 7 | 12 |
| MA Drowsiness | 1 | 0 | 0 |
| Any Irritability / Fussiness | 115 | 165 | 153 |
| ≥ G 2 Irritability / Fussiness | 42 | 79 | 68 |
| G 3 Irritability / Fussiness | 9 | 17 | 15 |
| Rel Irritability / Fussiness | 113 | 163 | 147 |
| G3 Rel Irritability / Fussiness | 9 | 17 | 15 |
| MA Irritability / Fussiness | 1 | 0 | 0 |
| Any Loss of appetite | 53 | 76 | 80 |
| ≥ G 2 Loss of appetite | 8 | 13 | 26 |
| G 3 Loss of appetite | 0 | 1 | 4 |
| Rel Loss of appetite | 48 | 73 | 77 |
| G3 Rel Loss of appetite | 0 | 1 | 4 |
| MA Loss of appetite | 0 | 0 | 0 |
| Any Fever | 22 | 34 | 29 |
| ≥ G 2 Fever | 0 | 0 | 2 |
| G 3 Fever | 0 | 0 | 0 |
| Rel Fever | 15 | 31 | 27 |
| G3 Rel Fever | 0 | 0 | 0 |
| MA Fever | 0 | 0 | 0 |
The solicited general symptoms assessed were Drowsiness, Irritability/Fussiness, Loss Of Appetite and Fever (defined as temperature ≥ 38.0°C). Any = any reports of the specific symptom irrespective of intensity grade; Grade 2 (G2) Drowsiness = Drowsiness that interfered with normal activity; Grade 2 Irritability/Fussiness = Moderate: Cried more than usual/interfered with normal activity; Grade 2 Loss of appetite = Ate less than usual/interfered with normal activity; Grade 2 Fever: \> 39.0 °C; Grade 3 (G3) Drowsiness/Irritability/Fussiness = symptom that prevented normal activity; Grade 3 Loss of appetite = Did not eat at all; Grade 3 Fever: \> 40.0 °C; Related (Rel) = Symptom which was assessed by the investigator as related to vaccination.
| Participants | Infanrix Hexa Group | Pediarix Group | Pentacel Group |
|---|---|---|---|
| Any Drowsiness | 97 | 132 | 109 |
| ≥ G 2 Drowsiness | 31 | 43 | 39 |
| G 3 Drowsiness | 8 | 7 | 4 |
| Rel Drowsiness | 94 | 126 | 108 |
| G3 Rel Drowsiness | 7 | 7 | 3 |
| MA Drowsiness | 0 | 0 | 0 |
| Any Irritability / Fussiness | 128 | 147 | 136 |
| ≥ G 2 Irritability / Fussiness | 53 | 70 | 61 |
| G 3 Irritability / Fussiness | 6 | 14 | 11 |
| Rel Irritability / Fussiness | 125 | 143 | 133 |
| G3 Rel Irritability / Fussiness | 6 | 13 | 11 |
| MA Irritability / Fussiness | 0 | 0 | 2 |
| Any Loss of appetite | 56 | 55 | 56 |
| ≥ G 2 Loss of appetite | 17 | 15 | 15 |
| G 3 Loss of appetite | 1 | 1 | 2 |
| Rel Loss of appetite | 52 | 51 | 55 |
| G3 Rel Loss of appetite | 1 | 1 | 2 |
| MA Loss of appetite | 0 | 0 | 1 |
| Any Fever | 47 | 36 | 35 |
| ≥ G 2 Fever | 2 | 3 | 2 |
| G 3 Fever | 0 | 0 | 0 |
| Rel Fever | 37 | 32 | 33 |
| G3 Rel Fever | 0 | 0 | 0 |
| MA Fever | 0 | 0 | 0 |
The solicited general symptoms assessed were Drowsiness, Irritability/Fussiness, Loss Of Appetite and Fever (defined as temperature ≥ 38.0°C). Any = any reports of the specific symptom irrespective of intensity grade; Grade 2 (G2) Drowsiness = Drowsiness that interfered with normal activity; Grade 2 Irritability/Fussiness = Moderate: Cried more than usual/interfered with normal activity; Grade 2 Loss of appetite = Ate less than usual/interfered with normal activity; Grade 2 Feve:r \> 39.0 °C; Grade 3 (G3) Drowsiness/Irritability/Fussiness = symptom that prevented normal activity; Grade 3 Loss of appetite = Did not eat at all; Grade 3 Fever: \> 40.0 °C; Related (Rel) = Symptom which was assessed by the investigator as related to vaccination.
| Participants | Infanrix Hexa Group | Pediarix Group | Pentacel Group |
|---|---|---|---|
| Any Drowsiness | 85 | 108 | 88 |
| ≥ G 2 Drowsiness | 23 | 37 | 25 |
| G 3 Drowsiness | 3 | 5 | 9 |
| Rel Drowsiness | 81 | 105 | 86 |
| G3 Rel Drowsiness | 3 | 5 | 9 |
| MA Drowsiness | 0 | 2 | 1 |
| Any Irritability / Fussiness | 126 | 135 | 122 |
| ≥ G 2 Irritability / Fussiness | 46 | 58 | 58 |
| G 3 Irritability / Fussiness | 6 | 15 | 11 |
| Rel Irritability / Fussiness | 121 | 129 | 120 |
| G3 Rel Irritability / Fussiness | 6 | 13 | 11 |
| MA Irritability / Fussiness | 0 | 3 | 1 |
| Any Loss of appetite | 45 | 58 | 53 |
| ≥ G 2 Loss of appetite | 11 | 13 | 15 |
| G 3 Loss of appetite | 1 | 2 | 2 |
| Rel Loss of appetite | 44 | 56 | 52 |
| G3 Rel Loss of appetite | 1 | 2 | 2 |
| MA Loss of appetite | 0 | 1 | 0 |
| Any Fever | 40 | 45 | 37 |
| ≥ G 2 Fever | 4 | 11 | 7 |
| G 3 Fever | 0 | 2 | 0 |
| Rel Fever | 35 | 39 | 35 |
| G3 Rel Fever | 0 | 2 | 0 |
| MA Fever | 1 | 2 | 1 |
The solicited general symptoms assessed were Drowsiness, Irritability/Fussiness, Loss Of Appetite and Fever (defined as temperature ≥ 38.0°C). Any = any reports of the specific symptom irrespective of intensity grade; Grade 2 (G2) Drowsiness = Drowsiness that interfered with normal activity; Grade 2 Irritability/Fussiness = Moderate: Cried more than usual/interfered with normal activity; Grade 2 Loss of appetite = Ate less than usual/interfered with normal activity; Grade 2 Fever: \> 39.0 °C; Grade 3 (G3) Drowsiness/Irritability/Fussiness = symptom that prevented normal activity; Grade 3 Loss of appetite = Did not eat at all; Grade 3 Fever: \> 40.0 °C; Related (Rel) = Symptom which was assessed by the investigator as related to vaccination.
| Participants | Infanrix Hexa Group | Pediarix Group | Pentacel Group |
|---|---|---|---|
| Any Drowsiness | 147 | 172 | 168 |
| ≥ G 2 Drowsiness | 67 | 88 | 81 |
| G 3 Drowsiness | 11 | 19 | 22 |
| Rel Drowsiness | 144 | 169 | 166 |
| G3 Rel Drowsiness | 11 | 18 | 21 |
| MA Drowsiness | 1 | 2 | 1 |
| Any Irritability / Fussiness | 164 | 182 | 177 |
| ≥ G 2 Irritability / Fussiness | 96 | 128 | 120 |
| G 3 Irritability / Fussiness | 18 | 35 | 30 |
| Rel Irritability / Fussiness | 161 | 180 | 175 |
| G3 Rel Irritability / Fussiness | 18 | 34 | 30 |
| MA Irritability / Fussiness | 1 | 3 | 3 |
| Any Loss of appetite | 95 | 111 | 117 |
| ≥ G 2 Loss of appetite | 28 | 32 | 39 |
| G 3 Loss of appetite | 2 | 3 | 6 |
| Rel Loss of appetite | 91 | 108 | 116 |
| G3 Rel Loss of appetite | 2 | 3 | 6 |
| MA Loss of appetite | 0 | 1 | 1 |
| Any Fever | 72 | 78 | 72 |
| ≥ G 2 Fever | 6 | 14 | 10 |
| G 3 Fever | 0 | 2 | 0 |
| Rel Fever | 61 | 74 | 69 |
| G3 Rel Fever | 0 | 2 | 0 |
| MA Fever | 1 | 2 | 1 |
Occurrence of specific adverse events, i.e., new onset chronic diseases (e.g. autoimmune disorders, asthma, type I diabetes and allergies)
| Participants | Infanrix Hexa Group | Pediarix Group | Pentacel Group |
|---|---|---|---|
| Number of Subjects With Specific Adverse Events (AEs). | 7 | 11 | 10 |
An unsolicited AE is any AE (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
| Participants | Infanrix Hexa Group | Pediarix Group | Pentacel Group |
|---|---|---|---|
| Number of Subjects With Unsolicited AEs. | 113 | 108 | 96 |
SAEs were defined as medical occurrences that resulted in death, were life threatening, required hospitalization or prolongation of hospitalization or resulted in disability/incapacity.
| Participants | Infanrix Hexa Group | Pediarix Group | Pentacel Group |
|---|---|---|---|
| Number of Subjects With Serious Adverse Events (SAEs). | 7 | 1 | 7 |
A seroprotected subject was defined a subject with antibody concentrations ≥ 0.1 IU/mL.
| Participants | Infanrix Hexa Group | Pediarix Group | Pentacel Group |
|---|---|---|---|
| Anti-T at Visit 5 | 118 | 123 | 107 |
| Anti-T at Visit 6 | 138 | 136 | 125 |
A seroprotected subject was defined a subject with antibody concentrations ≥ 0.1 IU/mL.
| Participants | Infanrix Hexa Group | Pediarix Group | Pentacel Group |
|---|---|---|---|
| Anti-D at Visit 5 | 128 | 123 | 115 |
| Anti-D at Visit 6 | 138 | 136 | 126 |
Concentrations were expressed as GMCs for the seropositivity cut-off of 0.1 IU/mL.
| IU/mL | Infanrix Hexa Group | Pediarix Group | Pentacel Group |
|---|---|---|---|
| Anti-T at Visit 5 | 0.327 (0.281 to 0.380) | 0.402 (0.340 to 0.474) | 0.340 (0.281 to 0.410) |
| Anti-T at Visit 6 | 9.212 (7.863 to 10.793) | 8.870 (7.668 to 10.261) | 6.880 (5.905 to 8.015) |
Concentrations were expressed as GMCs for the seropositivity cut-off of 0.1 IU/mL.
| IU/mL | Infanrix Hexa Group | Pediarix Group | Pentacel Group |
|---|---|---|---|
| Anti-D at Visit 5 | 0.701 (0.597 to 0.825) | 0.622 (0.514 to 0.753) | 0.764 (0.629 to 0.928) |
| Anti-D at Visit 6 | 8.334 (7.479 to 9.286) | 7.886 (6.972 to 8.92) | 8.537 (7.524 to 9.687) |
A seropositive subject was defined as a subject with antibody concentrations above to or equal to (≥) 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA, and 2.187 IU/mL for anti-PRN.
| Participants | Infanrix Hexa Group | Pediarix Group | Pentacel Group |
|---|---|---|---|
| Anti-PT at Visit 5 | 107 | 114 | 63 |
| Anti-FHA at Visit 5 | 130 | 130 | 113 |
| Anti-PRN at Visit 5 | 110 | 104 | 91 |
| Anti-PT at Visit 6 | 138 | 136 | 126 |
| Anti-FHA at Visit 6 | 138 | 136 | 126 |
| Anti-PRN at Visit 6 | 136 | 136 | 124 |
Concentrations were expressed as geometric mean concentrations (GMCs) for the following cut-offs:2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA, and 2.187 IU/mL for anti-PRN.
| IU/mL | Infanrix Hexa Group | Pediarix Group | Pentacel Group |
|---|---|---|---|
| Anti-PT Visit 5 | 5.3 (4.6 to 6.2) | 6.5 (5.6 to 7.7) | 3.1 (2.6 to 3.7) |
| Anti-FHA Visit 5 | 17.1 (14.7 to 19.9) | 21.8 (18.3 to 26.1) | 8.1 (6.6 to 9.9) |
| Anti-PRN Visit 5 | 6.8 (5.5 to 8.3) | 5.5 (4.5 to 6.6) | 6.0 (4.8 to 7.5) |
| Anti-PT Visit 6 | 71.4 (62.6 to 81.5) | 87.6 (76.6 to 100.2) | 55.5 (47.4 to 65.1) |
| Anti-FHA Visit 6 | 186.9 (165.1 to 211.5) | 250.4 (220.4 to 284.6) | 101.0 (86.2 to 118.3) |
| Anti-PRN Visit 6 | 208.0 (172.3 to 251.1) | 215.6 (176.1 to 263.8) | 130.5 (105.9 to 160.9) |
Booster response to PT, FHA and PRN antigens was defined as: * For subjects with pre-vaccination antibody concentration below the assay cut off, post-vaccination antibody concentration equal or above 4 times the assay cut-off. * For subjects with pre-vaccination antibody concentration between the assay cut off and below 4 times the assay cut-off, post-vaccination antibody concentration equal or above 4 times the pre-vaccination antibody concentration. * For subjects with pre-vaccination antibody concentration equal or above 4 times the assay cut-off, post-vaccination antibody concentration of at least two times the pre-vaccination antibody concentration. The assay cut off is 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA, and 2.187 IU/mL for anti-PRN.
| Participants | Infanrix Hexa Group | Pediarix Group | Pentacel Group |
|---|---|---|---|
| Anti-PT | 126 | 121 | 111 |
| Anti-FHA | 130 | 127 | 114 |
| Anti-PRN | 128 | 128 | 112 |
A seroprotected subject was defined as a subject with anti-PRP concentrations ≥ 0.15 µg/mL.
| Participants | Infanrix Hexa Group | Pediarix Group | Pentacel Group |
|---|---|---|---|
| Anti-PRP at Visit 5 | 91 | 122 | 94 |
| Anti-PRP at Visit 6 | 138 | 139 | 129 |
The cut-off for this assay was an anti-PRP concentration ≥ 1 µg/mL.
| Participants | Infanrix Hexa Group | Pediarix Group | Pentacel Group |
|---|---|---|---|
| Anti-PRP at Visit 5 | 23 | 71 | 47 |
| Anti-PRP at Visit 6 | 136 | 138 | 128 |
Antibody concentrations were expressed as GMCs for the seroprotection cut-off of 1 µg/mL.
| µg/mL | Infanrix Hexa Group | Pediarix Group | Pentacel Group |
|---|---|---|---|
| Anti-PRP at Visit 5 | 0.301 (0.242 to 0.373) | 0.987 (0.775 to 1.256) | 0.614 (0.458 to 0.822) |
| Anti-PRP at Visit 6 | 39.365 (31.520 to 49.164) | 51.140 (41.954 to 62.339) | 27.318 (21.140 to 35.302) |
A seroprotected subject was defined as a subject with anti-polio types 1, 2 and 3 titres ≥ 8 dilution.
| Participants | Infanrix Hexa Group | Pediarix Group | Pentacel Group |
|---|---|---|---|
| Anti-polio 1 | 124 | 121 | 100 |
| Anti-polio 2 | 119 | 122 | 109 |
| Anti-polio 3 | 123 | 126 | 80 |
Titres were expressed as geometric mean titres (GMTs) for the cut-off of 8 dilution.
| titres | Infanrix Hexa Group | Pediarix Group | Pentacel Group |
|---|---|---|---|
| Anti-polio 1 | 99.5 (79.4 to 124.8) | 107.4 (83.7 to 137.9) | 42.2 (32.6 to 54.6) |
| Anti-polio 2 | 94.9 (73.2 to 123.1) | 111.9 (88.0 to 142.4) | 51.2 (40.8 to 64.3) |
| Anti-polio 3 | 122.1 (95.1 to 156.9) | 160.4 (125.8 to 204.6) | 28.4 (20.6 to 39.1) |
A seroprotected subject was defined as a subject with anti-HBs antibody concentrations ≥ 10 mIU/mL.
| Participants | Infanrix Hexa Group | Pediarix Group | Pentacel Group |
|---|---|---|---|
| Number of Seroprotected Subjects Against Anti-HBs. | 131 | 128 | 105 |
Antibody concentrations were expressed as GMCs for the seroprotection cut-off of 10 mIU/mL.
| mIU/mL | Infanrix Hexa Group | Pediarix Group | Pentacel Group |
|---|---|---|---|
| Antibody Concentrations for Anti-HBs. | 328.7 (261.5 to 413.2) | 235.8 (188.2 to 295.5) | 149.4 (100.5 to 222.3) |
The solicited local symptoms assessed were pain, redness and swelling. Any = any reports of the specific symptom irrespective of intensity grade; above or equal (≥); Grade 2 Redness (Red)/Swelling (Swe): \> 5 millimeters (mm); Grade 3 Redness/Swelling: \> 20 mm; Grade 2 Pain = Moderate: cries/protests on touch; Grade 3 Pain = Severe: Cries when limb is moved/spontaneously painful. Grade = G; Medical Advice = MA.
| Participants | Infanrix Hexa Group | Pediarix Group | Pentacel Group |
|---|---|---|---|
| Any Pain, ActHIB/Hiberix | 61 | 64 | NA |
| ≥ G 2 Pain, ActHIB/Hiberix | 11 | 15 | NA |
| G 3 Pain, ActHIB/Hiberix | 1 | 2 | NA |
| MA Pain, ActHIB/Hiberix | 0 | 0 | NA |
| Any Pain, Infanrix/Pentacel | 62 | 74 | 59 |
| ≥ G2 Pain, Infanrix/Pentacel | 12 | 19 | 16 |
| G3 Pain, Infanrix/Pentacel | 2 | 3 | 2 |
| MA Pain, Infanrix/Pentacel | 1 | 0 | 0 |
| Any Red, ActHIB/Hiberix | 42 | 49 | NA |
| ≥ G 2 Red, ActHIB/Hiberix | 7 | 4 | NA |
| G 3 Red, ActHIB/Hiberix | 0 | 2 | NA |
| MA Red, ActHIB/Hiberix | 0 | 0 | NA |
| Any Red, Infanrix/Pentacel | 49 | 60 | 47 |
| ≥ G2 Red, Infanrix/Pentacel | 17 | 14 | 13 |
| G3 Red, Infanrix/Pentacel | 8 | 4 | 2 |
| MA Red, Infanrix/Pentacel | 2 | 0 | 0 |
| Any Swe, ActHIB/Hiberix | 29 | 29 | NA |
| ≥ G 2 Swe, ActHIB/Hiberix | 7 | 6 | NA |
| G 3 Swe, ActHIB/Hiberix | 0 | 2 | NA |
| MA Swe, ActHIB/Hiberix | 0 | 0 | NA |
| Any Swe, Infanrix/Pentacel | 42 | 44 | 35 |
| ≥ G2 Swe, Infanrix/Pentacel | 13 | 17 | 14 |
| G3 Swe, Infanrix/Pentacel | 5 | 7 | 4 |
| MA Swe, Infanrix/Pentacel | 2 | 0 | 0 |
The solicited general symptoms assessed were Drowsiness, Irritability/Fussiness, Loss Of Appetite and Fever (defined as temperature ≥ 38.0°C). Any = any reports of the specific symptom irrespective of intensity grade; Grade 2 (G2) Drowsiness = Drowsiness that interfered with normal activity; Grade 2 Irritability/Fussiness = Moderate: Cried more than usual/interfered with normal activity; Grade 2 Loss of appetite = Ate less than usual/interfered with normal activity; Grade 2 Fever: \> 39.0 °C and ≤ 40.0 °C; Grade 3 (G3) Drowsiness/Irritability/Fussiness = symptom that prevented normal activity; Grade 3 Loss of appetite = Did not eat at all; Grade 3 Fever: \> 40.0 °C; Related (Rel) = Symptom which was assessed by the investigator as related to vaccination.
| Participants | Infanrix Hexa Group | Pediarix Group | Pentacel Group |
|---|---|---|---|
| Any Drowsiness | 59 | 67 | 65 |
| ≥ G 2 Drowsiness | 18 | 20 | 17 |
| G 3 Drowsiness | 1 | 3 | 2 |
| Rel Drowsiness | 55 | 65 | 61 |
| G3 Rel Drowsiness | 1 | 3 | 2 |
| MA Drowsiness | 0 | 0 | 0 |
| Any Irritability / Fussiness | 86 | 94 | 76 |
| ≥ G 2 Irritability / Fussiness | 26 | 35 | 23 |
| G 3 Irritability / Fussiness | 3 | 4 | 4 |
| Rel Irritability / Fussiness | 85 | 92 | 68 |
| G3 Rel Irritability / Fussiness | 3 | 4 | 4 |
| MA Irritability / Fussiness | 0 | 0 | 1 |
| Any Loss of appetite | 47 | 47 | 46 |
| ≥ G 2 Loss of appetite | 8 | 9 | 11 |
| G 3 Loss of appetite | 1 | 2 | 2 |
| Rel Loss of appetite | 44 | 44 | 41 |
| G3 Rel Loss of appetite | 1 | 2 | 2 |
| MA Loss of appetite | 0 | 0 | 0 |
| Any Fever | 4 | 10 | 11 |
| ≥ G 2 Fever | 1 | 1 | 1 |
| G 3 Fever | 0 | 0 | 0 |
| Rel Fever | 2 | 10 | 9 |
| G3 Rel Fever | 0 | 0 | 0 |
| MA Fever | 0 | 2 | 1 |
Occurrence of specific adverse events, i.e., new onset chronic diseases (e.g. autoimmune disorders, asthma, type I diabetes and allergies)
| Participants | Infanrix Hexa Group | Pediarix Group | Pentacel Group |
|---|---|---|---|
| Number of Subjects With Specific AEs. | 4 | 1 | 1 |
An unsolicited AE is any AE (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
| Participants | Infanrix Hexa Group | Pediarix Group | Pentacel Group |
|---|---|---|---|
| Number of Subjects With Unsolicited AEs. | 37 | 35 | 41 |
SAEs were defined as medical occurrences that resulted in death, were life threatening, required hospitalization or prolongation of hospitalization or resulted in disability/incapacity.
| Participants | Infanrix Hexa Group | Pediarix Group | Pentacel Group |
|---|---|---|---|
| Number of Subjects With SAEs. | 1 | 0 | 1 |
Collected over Solicited local and general symptoms: during the 4-day (Day 0-Day 3) follow-up period after each dose. Unsolicited AEs: during the 31-day (Day 0-Day 30) follow-up period after each dose. SAEs: during the entire study period (from Month 0 to Month 17).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Infanrix Hexa Group | 0/195 (0%) | 8/195 (4.1%) | 188/195 (96.4%) |
| Pediarix Group | 0/194 (0%) | 1/194 (0.5%) | 190/194 (97.9%) |
| Pentacel Group | 0/196 (0%) | 8/196 (4.1%) | 187/196 (95.4%) |
| Event | Infanrix Hexa Group | Pediarix Group | Pentacel Group |
|---|---|---|---|
| Respiratory distressRespiratory, thoracic and mediastinal disorders | 3/195 | 0/194 | 0/196 |
| Parainfluenzae virus infectionInfections and infestations | 0/195 | 0/194 | 2/196 |
| Gastroenteritis viralInfections and infestations | 1/195 | 1/194 | 0/196 |
| LeukocytosisBlood and lymphatic system disorders | 1/195 | 0/194 | 0/196 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 1/195 | 0/194 | 0/196 |
| Meningitis viralInfections and infestations | 1/195 | 0/194 | 0/196 |
| Respiratory syncytial virus bronchiolitisInfections and infestations | 1/195 | 0/194 | 1/196 |
| Near drowningInjury, poisoning and procedural complications | 1/195 | 0/194 | 0/196 |
| DehydrationMetabolism and nutrition disorders | 1/195 | 0/194 | 1/196 |
| HyponatraemiaMetabolism and nutrition disorders | 1/195 | 0/194 | 0/196 |
| Event | Infanrix Hexa Group | Pediarix Group | Pentacel Group |
|---|---|---|---|
| IrritabilityPsychiatric disorders | 167/195 | 183/194 | 180/196 |
| SomnolenceNervous system disorders | 152/195 | 173/194 | 173/196 |
| Injection site painGeneral disorders | 141/195 | 162/194 | 152/196 |
| Injection site erythemaGeneral disorders | 112/195 | 129/194 | 116/196 |
| Decreased appetiteMetabolism and nutrition disorders | 112/195 | 126/194 | 127/196 |
| Injection site swellingGeneral disorders | 92/195 | 103/194 | 90/196 |
| PyrexiaGeneral disorders | 82/195 | 85/194 | 82/196 |
| Upper respiratory tract infectionInfections and infestations | 32/195 | 26/194 | 32/196 |
| CoughRespiratory, thoracic and mediastinal disorders | 17/195 | 8/194 | 7/196 |
| VomitingGastrointestinal disorders | 13/195 | 10/194 | 12/196 |
| Age, Continuous(Weeks) | Infanrix Hexa Group | Pediarix Group | Pentacel Group | Total |
|---|---|---|---|---|
| Mean | 8.5 ± 1.0 | 8.6 ± 1.1 | 8.6 ± 1.1 | 8.6 ± 1.1 |
| Sex: Female, Male(Participants) | Infanrix Hexa Group | Pediarix Group | Pentacel Group | Total |
|---|---|---|---|---|
| Female | 101 | 80 | 95 | 276 |
| Male | 94 | 114 | 101 | 309 |
| Race/Ethnicity, Customized(Participants) | Infanrix Hexa Group | Pediarix Group | Pentacel Group | Total |
|---|---|---|---|---|
| Asian - Japanese Heritage | 1 | 0 | 1 | 2 |
| African Heritage / African American | 16 | 9 | 20 | 45 |
| Asian - East Asian Heritage | 3 | 2 | 0 | 5 |
| White - Caucasian / European Heritage | 118 | 128 | 115 | 361 |
| Asian - Central/South Asian Heritage | 2 | 2 | 1 | 5 |
| White - Arabic / North African Heritage | 0 | 1 | 0 | 1 |
| Unspecified | 29 | 27 | 32 | 88 |
| American Indian or Alaskan Native | 15 | 15 | 17 | 47 |
| Native Hawaiian or Other Pacific Islander | 2 | 1 | 2 | 5 |
| Asian - South East Asian Heritage | 9 | 9 | 8 | 26 |
Plan to share: Yes — IPD is available via the Clinical Study Data Request site (click on the link provided below)
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · www.clinicalstudydatarequest.com
Ran from Apr 2014 to primary completion in Feb 2015, 9 months.
Results were first posted in Aug 2018, 3 years 5 months after primary completion. A results delay was requested in Aug 2017.
Of 36 industry-sponsored phase 3 interventional studies under Poliomyelitis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 21. This study's 9 months is below that.
Counting every sponsor, half of 45 studies reached it within 12 months; a quarter within 7 and three quarters within 21.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine